Advanced Search

National Health (Weighted average disclosed price - supplementary disclosure cycle A) Amendment Determination 2013 (No. 1) (No. PB 38 of 2013)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
PB 38 of 2013
National Health (Weighted average disclosed price – supplementary disclosure cycle A) Amendment Determination 2013 (No. 1)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this amendment determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.
Dated   4 July 2013
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price – supplementary disclosure cycle A) Amendment Determination 2013 (No. 1).
       (2)     This Determination may also be cited as PB 38 of 2013.
2              Commencement
                This Determination commences on the day after it is registered.
 
 
3              Amendments to PB 24 of 2013
Schedule 1 amends the National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2013 (PB 24 of 2013).
Schedule 1             Amendments
 
 
[1]      Schedule 1
 
             after:
 
12
Temozolomide
Capsule 140 mg
Oral
Temizole 140
627.72
 
insert:
 
12A
Temozolomide
Capsule 180 mg
Oral
Temodal
795.30
 
            
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au/Home.